Skip to content
naulon
Not checkedNot checked for notices yet.

MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies

Patricia Martin Romano, Eduardo Castanon, Antoine Hollebecque and 7 more

Journal of Immunotherapy and Precision Oncology · 2019

doi:10.4103/jipo.jipo_7_19 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Mesenchymal–epithelial transition factor (MET) amplification has been suggested either as a de novo or acquired mechanism of resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy. However, even if MET amplification has been widely described in the preclinical setting, only a few clinical data have confirmed the role of MET in the resistance to anti-EGFR treatment. A 60-year-old man presenting cholangiocarcinoma with EGFR amplification had a tumor response to anti-EGFR therapy. A new on-purpose tumor biopsy performed during tumor progression confirmed the known EGFR amplification as well as a new MET amplification. This clinical observation highlights the role of MET amplification as a mechanism of resistance to EGFR inhibitors.

Abstract licence: CC BY-NC-ND

References15

    15 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.